



(51) International Patent Classification:
C07K 14/18 (2006.01) *A61P 31/14* (2006.01)
A61K 39/12 (2006.01)

(21) International Application Number:
PCT/SG2024/050717

(22) International Filing Date:
05 November 2024 (05.11.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10202303148T 06 November 2023 (06.11.2023) SG

(71) Applicants: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10, Connexis North, Singapore, Singapore 138632 (SG). **NATIONAL CHUNG HSING UNIVERSITY**; 145 Xingda Rd., South Dist., Taichung City, 40227 (TW).

(72) Inventors: **PALUR, Venkata Raghuvamsi**; c/o Bioinformatics Institute – A*STAR, 30 Biopolis Street, #07-01 Matrix, Singapore 138671 (SG). **BOND, Peter John**; c/o Bioinformatics Institute – A*STAR, 30 Biopolis Street, #07-01 Matrix, Singapore 138671 (SG). **MARZINEK, Jan Kazimierz**; c/o Bioinformatics Institute – A*STAR, 30 Biopolis Street, #07-01 Matrix, Singapore 138671 (SG).

CHAO, Day-Yu; 145 Xingda Rd., South Dist., Taichung City, 40227 (TW).

(74) Agent: **DAVIES COLLISON CAVE ASIA PTE. LTD.**; 10 Collyer Quay, #07-01 Ocean Financial Centre, Singapore 049315 (SG).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: MODIFIED FLAVIVIRUS POLYPEPTIDE AND USES THEREOF




Figure 9(A)

(57) Abstract: The disclosure concerns engineered flavivirus envelope (E) polypeptides containing mutations in the stem- transmembrane domain, virus-like particles (VLPs) containing the engineered E polypeptides, and uses of the E polypeptides for treating and preventing flaviviral infections. The mutations in the stem-transmembrane domain may comprise two or more amino acid substitutions corresponding to positions 8, 11 or 15 of SEQ ID NO: 1 and the substitutions may be to a non-polar amino acid residue.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*